Editas Medicine (EDIT) and Intellia Therapeutics (NTLA) are genome research companies in Cambridge, MA founded just after the advent of CRISPR technology in 2012. They develop innovative treatments with gene editing, with a high concentration of Ph.D. and M.D. employees working in multiple collaborations with large pharmaceutical companies that provide additional capital and resources. Fiercely in competition with one another, they seek niches to call their own. NTLA has focused slightly more on blood-related disorders while EDIT has primarily taken aim at cancer and neurological disorders. Both have only reported negative earnings while they strive to bring viable treatments to market. Genome research has been a contentious topic for some time, so political climate is a big variable, and news events cause wild swings in the prices of both. NTLA’s market cap grew significantly in 2021, but it remains to be seen if this will give it a lasting advantage over EDIT.